Residual Renal Function in Hemodialysis and Inflammation

Area of Science:

• Nephrology
• Immunology
• Internal Medicine

Background:

• Residual renal function (RRF) significantly impacts outcomes in hemodialysis (HD) patients, affecting toxin clearance, fluid balance, quality of life, and mortality.
• Microinflammation, characterized by increased CD14+/CD16++ inflammatory monocytes, is observed in chronic kidney disease (CKD) even without clinical signs of inflammation.
• The relationship between RRF and specific inflammatory markers in HD patients remains underexplored.

Purpose of the Study:

• To investigate the association between residual renal function (RRF) and inflammatory parameters in patients undergoing chronic hemodialysis.
• To determine if reduced inflammation is linked to the presence of RRF in the HD population.

Main Methods:

• A cross-sectional observational study involving 69 adult patients on chronic HD for at least six months.
• Data collected included demographics, laboratory results, and HD technique details.
• Residual renal function was assessed by average 24-hour urine urea and creatinine clearance; inflammation was evaluated using C-reactive protein, beta-2 microglobulin, albumin levels, and peripheral blood monocyte subpopulations (CD14+/CD16++).

Main Results:

• 43.5% of patients (30/69) exhibited residual renal function.
• Patients with RRF demonstrated significantly lower concentrations of C-reactive protein (6.2 vs 21.4 mg/L, P = 0.038).
• A lower percentage of non-classical CD14+/CD16++ monocytes was observed in patients with RRF (14.6% vs 28.3%, P = 0.02).

Conclusions:

• Residual renal function in hemodialysis patients is associated with lower levels of key inflammatory markers, including C-reactive protein and specific monocyte populations.
• These findings underscore the importance of preserving residual renal function as a therapeutic goal in hemodialysis management.
• Further research can explore the mechanisms linking RRF and reduced inflammation.